The FDA approved RiVive, an over-the-counter version of naloxone nasal spray from Harm Reduction Therapeutics. It’s the second such approval from the FDA this year, following an affirmative decision in March for OTC Narcan.
The White House launched a new initiative to address the country’s opioid crisis — a dashboard tracking non-fatal opioid overdoses. The new tool is meant to track overdose clusters to inform better medical responses and preparedness.
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
The age-old drug naloxone has undergone a resurgence in recent years as a tool for reversing opioid overdoses. Could it also help control other addictive disorders, such as bulimia nervosa?
In February of this year, the FDA approved the Narcan nasal spray to revive patients that had overdosed on opioid drugs. But the real story of 2016 was how widely that antidote was needed. The epidemic reached all corners of America in deadly new synthetic forms, raising unprecedented awareness about the dangers of opioid use -- without yet bringing the death toll down.
Currently Amphastar Pharmaceuticals has dominated the market producing the drug naloxone which can reverse a heroin overdose. With more and more people struggling with heroin addiction in the country, is it fair that the company has practically doubled the price of the drug just this year?
Drugs that reverse the effects of a heroin or opioid painkiller overdose will be put in the hands of police departments this year, which could lead to more recovery at the scene as opposed to more arrests. Good news right? But this new approach comes with a price. Police and public health officials from New […]
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.